26 March 2021 Insight Biotech patents – assessing validity for broad claims This article considers the application of the Supreme Court's ruling in Regeneron v Kymab to a patent dispute between Illumina and MGI. When you have a broadly defined biotech invention, how much disclosure is required for it to avoid an insufficiency attack? Bookmark this page 5 min read
5 March 2021 Insight The UK’s new medicines and medical devices regime – next steps This article considers the newly finalised Medicines and Medical Devices Act 2021. How will this the affect life science industry in the UK after Brexit? Bookmark this page 6 min read
18 February 2021 News 4Basebio admission to AIM and transfer to UK Mills & Reeve has acted for 4Basebio UK Societas on the Company’s successful admission to AIM and move from Germany to the UK, one of the final cross-border EU transfers to take place. Bookmark this page 2 min read
26 January 2021 News Diurnal licensing deal for paediatric treatment in China Mills & Reeve has advised longstanding client Diurnal Group on an exclusive licensing transaction for the commercialisation of its product Alkindi® in China. Bookmark this page 2 min read
A sense of direction for AI Artificial intelligence is bringing amazing advances to our world, particularly to the health and care sector. But, is it time for global, joined-up regulation? Read our research report conducted with AMRC. A sense of direction for AI